AMSA and peptichemio in the treatment of advances metastatic breast cancer: a phase II study.

Abstract

A combination of AMSA and peptichemio was evaluated in patients with advanced breast cancer refractory to conventional chemotherapy. Of 33 evaluable patients, five patients (15%) achieved partial remission, two patients (6%) had less-than-partial remission, nine patients (27%) had stable disease, and seventeen patients (52%) had progressive disease. The median duration of response was 6 months (range: 3-8 months). The median duration of stable disease was 5 months (range: 2-7 months). Myelosuppression was the dose-limiting toxicity. This combination of AMSA and peptichemio did not result in an improved response rate or duration of remission compared to the previous experience with single-agent therapy with either of these agents.

• Authors: A U Buzdar, S S Legha, G N Hortobagyi, K C Powell, G R Blumenschein, G P Bodey
• Journal: American journal of clinical oncology (Am J Clin Oncol) Vol. 5 Issue 4 Pg. 383-7 (Aug 1982) ISSN: 0277-3732 [Print] United States
• PMID: 6896794 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Aminoacridines
• Antineoplastic Agents
• Amsacrine
• Peptichemio
• Melphalan

Topics

• Adult
• Aged
• Aminoacridines (administration & dosage, adverse effects)
• Amsacrine
• Antineoplastic Agents (administration & dosage, adverse effects)
• Breast Neoplasms (drug therapy)
• Drug Evaluation
• Drug Therapy, Combination
• Female
• Humans
• Leukopenia (chemically induced)
• Melphalan (analogs & derivatives)
• Middle Aged
• Neoplasm Metastasis
• Peptichemio (administration & dosage, adverse effects)
• Thrombocytopenia (chemically induced)